

Resource Summary Report

Generated by [RRID](#) on Aug 6, 2026

CD19 Antibody, anti-human, FITC, REAfinity™

RRID:AB_2726198

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-113-645, RRID:AB_2726198

Antibody Information

URL: http://antibodyregistry.org/AB_2726198

Proper Citation: Miltenyi Biotec Cat# 130-113-645, RRID:AB_2726198

Target Antigen: CD19

Host Organism: human

Clonality: monoclonal

Comments: Info: This product is a higher concentration for optimized use in multicolor flow cytometry panels. It replaces product cat # 130-110-248. (RRID:AB_2655805).

Antibody Name: CD19 Antibody, anti-human, FITC, REAfinity™

Description: This monoclonal targets CD19

Target Organism: human

Clone ID: clone REA675

Antibody ID: AB_2726198

Vendor: Miltenyi Biotec

Catalog Number: 130-113-645

Record Creation Time: 20250819T211211+0000

Record Last Update: 20250819T221106+0000

Ratings and Alerts

No rating or validation information has been found for CD19 Antibody, anti-human, FITC, REAfinity™.

No alerts have been found for CD19 Antibody, anti-human, FITC, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 3 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Krug A, et al. (2024) Inhibition of choline metabolism in an angioimmunoblastic T-cell lymphoma preclinical model reveals a new metabolic vulnerability as possible target for treatment. Journal of experimental & clinical cancer research : CR, 43(1), 43.

Prinz LF, et al. (2024) An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL. Cell reports. Medicine, 5(2), 101421.

Martin-Rufino JD, et al. (2023) Massively parallel base editing to map variant effects in human hematopoiesis. Cell, 186(11), 2456.